delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
A double-blind cross-over trial with delta 9-tetrahydrocannabinol (THC) and placebo was employed to test the antiemetic effect on nausea and vomiting after MOPP-therapy. Although THC had remarkable antiemetic effects, the side effects were severe. Most patients preferred the nausea and the vomiting after MOPP-therapy to the use of THC. A relation between the antiemetic action or the side-effects and the blood-level of THC could not be demonstrated.
D000328:Adult; D000932:Antiemetics; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D013759:Dronabinol / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D008875:Middle Aged; D010919:Placebos; D011241:Prednisone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D000932:Antiemetics; D000970:Antineoplastic Agents; D010919:Placebos; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D013759:Dronabinol; D011241:Prednisone